HyNic-4FB chemistry serving antibody-drug conjugates (ADCs)

ChromaLink technology

Challenges and limitations of ADC development

One of the major challenges of modern medicine is to find a safe cancer therapy. The Food and Drug Administration has approved Adcetris® (brentuximab vedotin) and Kadcyla® (ado-trastuzumab emtansine) that are considered as powerful treatments against cancer. They are good examples of antibody-drug conjugates (ADCs). The principle is to link a drug, that can be cytotoxic, to an antibody able to target cancer cells. Unfortunately, the development of ADCs faces some difficulties. Indeed, depending on the method for the conjugation, the ADC can be highly heterogenous.

A simple and robust conjugation, 4FB linker to HyNic linker

As used by Rongsheng E. Wang et in 2015, the S-4FB linker can be used to generate antibody conjugate HLCX-dasatinib (doi:10.1021/jacs.5b00620). Since that first step, more improvement were made. Indeed, we can combine the S-4FB to HyNic-biomolecules. The conjugation is simple, rapid and stable. Trilink Biotechnologies provides that technology under the label ChromaLink. The principle is illustrated on the picture below.

Antibody and biomolecule conjugation with HyNic-4FB chemistry
Antibody and biomolecule conjugation with HyNic-4FB chemistry

There is also a cleavable S-4FB linker and a MHPH (Maleimide HyNic) crosslinker for maleimide-based ADCs.

ChromaLink technology allows:

  • Rapid and efficient conjugation (>80%)
  • Simple quantification of the conjugate by simple UV scan
  • High stability (pH2-100, 95°C)
  • Preserves activity of the drug or the enzyme
  • Reproducibility and ADC homogenous population

The conjugation can be done between several types of biomolecules, peptides, proteins, enzymes, oligonucleotides

So it allows also drug conjugation to oligonucleotides such as aptamers for another type of cell targeting.

Interested in learning more? Leave your questions or comments below, I’ll be pleased to answer!

views

Leave a Reply

Your email address will not be published. Required fields are marked *

Related posts

Drug Discovery
Drug Discovery, Supplying Discovery Tools
Drug Discovery

Subscribe to our newsletter